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Abstract
Background: Macrophages (Mθ) play a central role in the innate immune response and in the pathology of
chronic inflammatory diseases. Macrophages treated with Th2-type cytokines such as Interleukin-4 (IL-4) and
Interleukin-13 (IL-13) exhibit an altered phenotype and such alternatively activated macrophages are important
in the pathology of diseases characterised by allergic inflammation including asthma and atopic dermatitis. The CC
chemokine Thymus and Activation-Regulated Chemokine (TARC/CCL17) and its murine homologue (mTARC/
ABCD-2) bind to the chemokine receptor CCR4, and direct T-cell and macrophage recruitment into areas of
allergic inflammation. Delineating the molecular mechanisms responsible for the IL-4 induction of TARC
expression will be important for a better understanding of the role of Th2 cytokines in allergic disease.
Results:  We demonstrate that mTARC mRNA and protein are potently induced by the Th2 cytokine,
Interleukin-4 (IL-4), and inhibited by Interferon-γ (IFN-γ) in primary macrophages (Mθ). IL-4 induction of mTARC
occurs in the presence of PI3 kinase pathway and translation inhibitors, but not in the absence of STAT6
transcription factor, suggesting a direct-acting STAT6-mediated pathway of mTARC transcriptional activation.
We have functionally characterised eleven putative STAT6 sites identified in the mTARC proximal promoter and
determined that five of these contribute to the IL-4 induction of mTARC. By in vitro binding assays and transient
transfection of isolated sites into the RAW 264.7 Mθ cell-line, we demonstrate that these sites have widely
different capacities for binding and activation by STAT6. Site-directed mutagenesis of these sites within the
context of the mTARC proximal promoter revealed that the two most proximal sites, conserved between the
human and mouse genes, are important mediators of the IL-4 response.
Conclusion: The induction of mTARC by IL-4 results from cooperative interactions between STAT6 sites within
the mTARC gene promoter. Significantly, we have shown that transfer of the nine most proximal mTARC STAT6
sites in their endogenous conformation confers potent (up to 130-fold) IL-4 inducibility on heterologous
promoters. These promoter elements constitute important and sensitive IL-4-responsive transcriptional units
that could be used to drive transgene expression in sites of Th2 inflammation in vivo.
Published: 29 November 2006
BMC Molecular Biology 2006, 7:45 doi:10.1186/1471-2199-7-45
Received: 20 August 2006
Accepted: 29 November 2006
This article is available from: http://www.biomedcentral.com/1471-2199/7/45
© 2006 Liddiard et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Molecular Biology 2006, 7:45 http://www.biomedcentral.com/1471-2199/7/45
Page 2 of 18
(page number not for citation purposes)
Background
Macrophages (Mθ) are key protagonists in both frontline
defence against pathogens and regulation of the subse-
quent adaptive immune response. Chemokines secreted
by Mθ during an inflammatory response are important
determinants of the ensuing immune reaction, regulating
the types and amounts of effector cells recruited to execute
an appropriate response [1-3]. Alternatively-activated Mθ
[4-6] play important roles in wound healing [7,8] and the
resolution of inflammation [9,10], as well as contributing
to allergic inflammation, hence IL-4-mediated signalling
in Mθ is critical to many important human diseases.
The receptor for Thymus and Activation-Regulated Chem-
okine (TARC/CCL17), CCR4 [11], is most highly
expressed on differentiated Th2 lymphocytes [12], as well
as CD25+ regulatory T cells [13] and CLA+ (cutaneous lym-
phocyte antigen) skin-homing lymphocytes [14]. Thus,
TARC is implicated in the recruitment of Th2 lymphocytes
and the maintenance of Th2 immune responses [15], as
well as in the suppression of classically-activated Mθ [16].
TARC expression levels correlate with the severity of dis-
ease in some chronic allergic pathologies, including
asthma [17-19], atopic dermatitis [20] and cutaneous
lupus erythematosus [21]. Additionally, in vivo neutralisa-
tion of TARC can limit Th2 lymphocyte recruitment and
inflammation [22-24], underlining the significance of this
chemokine to allergic pathologies and the importance of
understanding how its expression is regulated in cells of
the innate immune system.
Expression of the CC chemokine TARC has been shown to
be up-regulated in human monocytes and Mθ treated with
the Th2 cytokines, IL-4 and IL-13 [15,25], and inhibited
by IFN-γ [25]. Murine TARC (mTARC[26]/ABCD-2[27])
shares 66% identity with human TARC at the amino acid
level and is similarly chemotactic for CCR4+ cells. mTARC
has been shown to be expressed by Langerhans cells
[28,29] and dendritic cells (DC) [30,31], but not by Mθ
treated with IFN-γ and LPS [30]. The roles of alternatively
activated Mθ in the production of mTARC and the mech-
anisms underlying the IL-4 induction of this chemokine
in Mθ have not been fully addressed.
STAT6 is the sole STAT protein capable of signal transduc-
tion from the IL-4 receptor and activates the transcription
of inflammatory mediators including eotaxin (CCL11)
[32], Yml [33] and 12/15-lipoxygenase [34]. STAT6 also
plays an integral role in the biology of alternatively-acti-
vated Mθ via activation of the myeloid transcription fac-
tor, Tfec [35] as well as arginase I [36]. Following ligand
binding, JAK (Janus Kinase) proteins associated with the
IL-4 receptor phosphorylate STAT6 monomers, allowing
them to dimerise, translocate to the nucleus and activate
gene transcription by binding to palindromic
TTC(N)4GAA DNA consensus sites [37-39]. The C-termi-
nus of STAT dimers contains the transactivation domain
(TAD) [40], whereas the N-terminus may stabilise interac-
tions between STAT dimers bound at tandem low-affinity
sites less than 20 bp apart, resulting in enhanced tran-
scriptional responses from these promoters [41].
In this paper, we demonstrate for the first time that IL-4 is
a key inducer of TARC mRNA and protein in murine Mθ
and confirm that this induction is mediated by the tran-
scription factor, STAT6. Of eleven potential STAT6 sites
identified within the murine TARC (mTARC) proximal
promoter, we show that five of these sites contribute dif-
ferentially and cooperatively to the IL-4-inducibility of the
TARC promoter. These studies have also enabled us to
generate a potent IL-4-inducible element based on the
natural configuration of mTARC promoter STAT6 sites
that could be used to drive expression of specific trans-
genes in response to IL-4 with potential therapeutic bene-
fit.
Results
Murine TARC is up regulated by IL-4 in macrophages
BIOgel-elicited peritoneal Mθ were stimulated with classi-
cal Thl1 (IFN-γ) or Th2 (IL-4) cytokines or LPS (Figure 1).
RNA and culture supernatant samples were simultane-
ously prepared from single wells at defined time points
over a 72-hour period and were analysed for murine TARC
(mTARC) mRNA and protein expression. Cell viability
over this time period was independently confirmed by
MTT assay (data not shown). mTARC mRNA was almost
completely absent from untreated cells at all time points
(Figure 1A), and was most potently induced by IL-4, con-
sistent with its reported expression pattern in human Mθ
[15,25]. Onset of mTARC induction by IL-4 was seen at 4
hours and peaked at 24 hours, when mTARC mRNA
induction over untreated samples was more than 1,000-
fold. IL-13 was also a potent inducer of mTARC mRNA at
this time point, as measured by semi-quantitative PCR
(data not shown). After 24 hours, there was a dramatic
decline in mTARC mRNA levels detected in the IL-4-
treated samples, although expression had still not
returned to basal level within 72 hours. Neither LPS nor
IFN-γ stimulated up-regulation of mTARC mRNA, even
though these treatments resulted in significant induction
of IP-10 (IFN-γ-inducible protein 10, CXCL10) [42]
mRNA [see Additional file 1]. IFN-γ was also found to
inhibit mTARC mRNA induction by IL-4 when added
either prior to or concurrently with IL-4 treatment [see
Additional file 1]. mTARC protein expression closely fol-
lowed the mRNA profile in time of onset and duration
(Figure 1B). As with the mRNA, mTARC protein expres-
sion was only detected in IL-4-treated samples. mTARC
protein first appeared in the culture supernatants of IL-4-
treated cells after 24 hours. Protein levels reached a peakBMC Molecular Biology 2006, 7:45 http://www.biomedcentral.com/1471-2199/7/45
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at 48 hours, and had not declined greatly by 72 hours, as
previously documented for human PBMCs [25] and T
lymphocytes [43].
Induction of TARC mRNA by IL-4 is mediated by STAT6 
and does not require de novo protein synthesis
The kinetics of the IL-4 induction of TARC are such that
several different mechanisms of promoter activation
might be possible [44], including activation of PI3 kinase
[45,46] or the IL-4-activated transcription factor, PPARγ
[47,48]. However, mTARC induction by IL-4 was not
inhibited by the PI3 kinase inhibitor, wortmannin, or the
PKC inhibitor, chelerythrine chloride (data not shown)
and mTARC mRNA was not up regulated by the PPARγ
agonists, rosiglitazone, troglitazone or 15-deoxy-Δ12,14-
prostaglandin J2 (data not shown). As STAT6-mediated
gene transcription does not require de novo protein syn-
thesis [49], we measured mTARC induction by IL-4 in the
presence of the translational inhibitor, cycloheximide.
Cells were pre-treated for 2 hours with doses of cyclohex-
mTARC mRNA and protein are strongly IL-4-induced and display temporal congruence Figure 1
mTARC mRNA and protein are strongly IL-4-induced and display temporal congruence. C57BL/6 peritoneal BIO-
gel-elicited Mθ were cultured in OptiMEM alone (untreated) or in the presence of 20 ng/ml recombinant murine IL-4 or EFN-γ 
or 40 ng/ml LPS. A, Total RNA was harvested at the designated time points and subjected to real-time PCR. Relative mTARC 
cDNA copy number was interpolated from an internal standard curve and expressed as a ratio of mTARC/HPRT +/- SEM, the 
results shown are representative of more than 3 similar experiments. B, Supernatants were collected at same time points for 
protein determination by ELISA. Protein results represent data from duplicate samples +/- SD.
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imide found to abrogate 35S-methionine incorporation.
IL-4 was added and cells cultured for a further 4 or 24
hours before RNA harvest. mTARC mRNA was still
induced by IL-4 in the presence of both cycloheximide
doses at 4 hours and at 24 hours [see Additional file 2].
Furthermore, cycloheximide treatment resulted in
mTARC superinduction, as has been noted for early
immediate genes such as COX-2 [50]. These results indi-
cate that de novo protein synthesis is not a pre-requisite of
the IL-4 induction of mTARC and may actually act to
reduce mTARC transcription.
To determine the involvement of STAT6 in mTARC regu-
lation, thioglycollate-elicited peritoneal Mθ were isolated
from both wild-type and STAT6-/- [51] mice and treated
with IL-4 for 24 hours (Figure 2A). Whereas the wild-type
BALB/c Mθ exhibited the characteristic strong IL-4 induc-
tion of mTARC mRNA, the STAT6-/- Mθ did not, demon-
strating an absolute requirement of STAT6 for the IL-4-
mediated up regulation of mTARC in Mθ. Binding of
STAT6 to the endogenous mTARC promoter was also con-
firmed in ChIP assays using IL-4-treated bone marrow-
derived Mθ (Figure 2B) in the presence or absence of a
STAT6 blocking peptide. This experiment shows that
STAT6 is rapidly recruited to the mTARC promoter in IL-4
treated Mθ.
Identification of putative STAT6 binding sites in the 
murine TARC proximal promoter
We obtained the sequence for the MDC-Fractalkine-TARC
loci on mouse chromosome 8 from the Celera and Sanger
Centre [52] databases and identified eleven putative
STAT6 binding sites (called STAT6 T1-T11 in order of
proximodistal location) within a 1.2 kb region 5' of the
mTARC coding sequence (Figure 3). Three of the putative
mTARC STAT6 sites (T2, T4 and T6) conform to the pub-
lished consensus sequence for STAT6 binding,
TTC(N)4GAA [39]. The T1 site has TTC(N)3GAA spacing,
to which STATs 1, 3, 4 and 5 [53-55] can bind, as well as
STAT6 [33,56]. The remaining seven sites represent varia-
tions of the TTC(N)4GAA consensus, each possessing 4
central nucleotides flanked by the A and T residues that
delineate the binding site. The T1 and T2 sites were found
to be highly conserved between human and mouse, sug-
gesting they may be of particular importance in mediating
TARC induction by IL-4 in both species.
The IL-4 induction of mTARC is STAT6-dependent Figure 2
The IL-4 induction of mTARC is STAT6-dependent. A, Peritoneal thioglycollate-elicited Mθ from BALB/c wild-type or 
BALB/c STAT6-/- mice were treated +/- lOng/ml recombinant murine IL-4 for 24 hours. Total RNA was harvested and sub-
jected to semi-quantitative RT-PCR with mTARC or β2M (housekeeping gene) primers. Chromatin immunoprecipitation 
experiments show STAT6 binding to the mTARC promoter. B, Bone marrow-derived Mθ from Balb/c and STAT6-/- 
were treated with 10 ng/ml recombinant murine IL-4 for the time periods shown before being formaldehyde fixed and soni-
cated. PCR using mTARC promoter primers was performed on DNA immunoprecipitated with STAT6 antibody in the pres-
ence or absence of a specific STAT6 blocking peptide. Amplification of 1/100th of input DNA and no input DNA controls were 
routinely performed in each ChIP experiment for positive and negative controls, respectively.
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Contribution of STAT6 sites T1-T11 to the IL-4 induction 
of murine TARC
To analyse the relative contribution of sites T1-T11 to the
IL-4 induction of transcription, we initially generated a 5'
deletion series of promoter constructs in which these
putative STAT6 sites were sequentially lost from a full-
length -1173 construct containing all eleven putative sites
and the transcriptional start site (Figure 4). The nomencla-
ture of the mTARC promoter plasmids is derived from
assigning the start point of transcription of the mTARC
gene as + 1 [30]. These constructs were co-transfected into
the RAW 264.7 Mθ cell line with a STAT6 expression vec-
tor to ensure transcription factor expression was not rate
limiting or variable between samples. When stimulated
with IL-4 for 18 hours, these deletion constructs demon-
strated differential activation. Activation of full-length -
1173 mTARC promoter was reproducibly induced at least
12-fold by IL-4, whereas the minimal mTARC promoter
(mTARC -128), which lacks any STAT6 sites, was not at all
IL-4-responsive. Deletion of DNA sequences between -
649 and -498 (containing T5 and T6 sites) and -467 and -
128 (containing T1 and T2 sites) reduces IL-4 induction,
indicating that these two regions are important to the
overall IL-4 response of the mTARC promoter.
-1173 bp mTARC promoter and putative STAT6 sites Figure 3
-1173 bp mTARC promoter and putative STAT6 sites. Sequence of the MDC-Fractalkine-TARC locus on mouse chro-
mosome 8 was obtained from the Celera database and verified using the Sanger Centre database. Putative STAT6 sites in the 
proximal mTARC promoter were identified using low stringency searches using Genomatix MatInspector Release Professional 
6.1 (November 2002) and the Transcription Element Search System (TESS). Sites conserved between human and mouse are 
written in italics. ATGindicates translation start codon, arrow indicates transcription start site and sequence positions are 
indicated as superscript, the start point of transcription of the mTARC gene as denoted + 1 [30].
AGTGTCTGCTAGCACATGAGTGCAAAACACCTATGCACACAAATGTAATAAATAAATGTTAATAAATTAAAATTTT
AAAGAGTAAAACACACGGCGGCACATGCCTTATCTGTGAGACACTCTGGGTCACACTGCAAAGCAGTGACATTTCC
CTTTATTGTGATAGCGTCTCACCAGCACCTGTGAACCCCGGTAGCTCAGGCTGGCCTCAAACTTGGAACCTTCCTA
CATCAGCCTCCCCAGTAGCTGGGATGCCGGTTCTTTTTCTCAGTAAACCCTGGCTTTGCTTAATAGTGACTTGTCC
TGAAACTCTTTTCTGGGCACTGTTGTTAACAGTCTGGGTATGCTGAAAATTCACACAGATTTCTTAACAGTCTGCT
TAAGGCCTGGGGATGCTCTATGGGCTTCTAGGGCAGCCTCTGGCATGCAGCTCCTATAGAGGTGAGCATCGCCCCC
CCCCACACACACACACCATTCATTCTGCTCATAACAGAAACGAGGTGGTGCTCTATTTCTGGGAGCTGAGCTTTCC
AACCCACTAAAGCACACATGCAGAAACACCATGATTAAAGCCCCTCTCAGCTTAGCCTCCTGGGGTAAGGGCCAGC
CTGGGGAAGGACAGGAAGACAGGCTCAGCTTCAGCTGAACCTCTGGGTTCCCCAAAATAGGGTGGGACTAGGCCTC
TTCTACTGAACATCCCTGTAACCTGCTCACCCTCCTGTGGACCTTCTGGACCCCAGAGCCCTGACTGGCATAGTCC
CTATGATCTCTGTTTGGTCCCCTACCCTGCCTCCACAGGGTACCAGGCACAAAGGAAGTTCACCAGTACTAGGACA
AGGGATGAGATGAGTTGAGGCTGAGGCCTTGGATCCTGCTAATAGAGGAACCAAGAAATGTTCCCTTTGAAAAGAG
AAGTAAGTCATTGCCCTTACCCCAGACACAGACCCCCTCCCCTGTCCCGAGTCGAGTGACCATTCTCTGGAAAGCC
ACAAACATTCCCAAGCTGGGCTTCTACTAAGTTATCTCAAATTCTTTGAATTTCTCTAGTCTGGAAGGATTATAGG
AGGGGACAGGAAGCGTGGGATAACCTCCAGAGAGGTTAAATAGGTCACCTCAATGCTGGGCACCAAGACAGGCAGA
AGGACCCATGAAGACCTTCACCTCAGCTTTTGGTACCATG
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The STAT6 binding capacity of each putative STAT6 site
was tested in vitro by EMSA (Figure 5). Nuclear extracts
from C57BL/6 BIOgel-elicited Mθ untreated or treated
with IL-4 or IFN-γ for 1 hour were prepared and incubated
with radiolabelled probes for each individual mTARC
STAT6 site. The probes containing the T2 and T4 STAT6
consensus sites were capable of binding a complex of the
predicted mobility for STAT6 specifically present in
extracts from IL-4-treated samples (Figure 5A). The T1
promiscuous STAT binding site and the T11 imperfect
consensus site were also able to bind this complex. Sur-
prisingly, the probe containing the T6 'perfect' STAT6 con-
sensus site did not bind this complex (data not shown).
The T3 and T5-T10 probes bound larger complexes that
were not specific to IL-4-treated samples (data not
shown). The IL-4-induced complex bound by T1, T2, T4
and T11 was supershifted by a STAT6-specific Ab, but not
by a STAT1 Ab, further confirming that it contained STAT6
(Figure 5B). Both unlabelled T1 and T4 probes added in
100-fold molar excess were able to efficiently compete the
STAT6 complex from the T1, T2, T4 and T11 probes. These
experiments show that STAT6 can bind to sites with
TTC(N)3GAA as well as TTC(N)4GAA spacing in the
mTARC promoter and that perfect STAT6 consensus
sequence is not the only determinant of STAT6 binding.
The binding capacity of an oligonucleotide in vitro is not
always representative of its functional activity within cells
[57] and so we compared the relative IL-4-inducibility of
individual key mTARC putative STAT6 sites in transient
transfection experiments. We generated luciferase reporter
plasmids containing trimers of the T1, T2, T4 and T11
sites, which bound STAT6 in EMSA assays, and also of the
T6 perfect consensus site, which did not bind STAT6, but
The eleven putative STAT6 sites within the proximal mTARC promoter contribute differentially to the IL-4 induction Figure 4
The eleven putative STAT6 sites within the proximal mTARC promoter contribute differentially to the IL-4 
induction. Ten million RAW 264.7 cells were co-transfected with 5 μg mTARC promoter 5' deletion luciferase constructs 
and 3 μg STAT6 expression vector, β-galactosidase expression vector (1 μg) was also co-transfected to control for transfec-
tion efficiency. Identical transfections were pooled and plated into duplicate wells for each treatment. Cells were treated +/- 20 
ng/ml recombinant murine IL-4 for 16–18 hours before being harvested and assayed for luciferase and β-galactosidase activity. 
Data are representative of 2 transfections and results are expressed as Luciferase Activity normalised for β-galactosidase activ-
ity +/- SD. Deletion construct end points are marked and correspond to the sequence information contained in Figure 3. The 
putative STAT6 sites contained in each construct are also indicated.
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Probes containing the mTARC putative STAT6 sites T1, T2, T4 and T11 bind stable STAT6 complexes in vitro Figure 5
Probes containing the mTARC putative STAT6 sites T1, T2, T4 and T11 bind stable STAT6 complexes in vitro. 
Nuclear extracts were prepared from C57BL/6 peritoneal BIOgel-elicited Mθ treated +/- 20 ng/ml recombinant murine IL-4 or 
TFN-γ for 1 hour. Extracts were incubated with radiolabelled mTARC T1-11 putative STAT6 site probes (data not shown for 
T3 and T5-T10, which did not bind STAT6) for 15 minutes before EMSA was performed (A). Specificity of binding was demon-
strated by pre-incubating nuclear extracts +/- specific STAT Abs or excess cold competitor mTARC T1 or T4 putative STAT6 
site probes (B). Bands labelled * represent nonspecific DNA-protein interactions, FP shows the top of the free probe and -Ori 
denotes the origin of the gel.
*
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* *
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Ori
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has perfect consensus STAT6 binding sequence and might
contribute to the activity of sequence region -649 to -498
(Figure 4).
Oligonucleotides consisting of three copies of the EMSA
sequence for each of the sites were cloned onto a heterol-
ogous promoter, the minimal Emr1 -40 promoter [58], in
pGL3 Basic. The Emr1 -40 minimal promoter was selected
for its low basal activity in Mθ, lack of inducibility by IL-4
(Figure 8A) and absence of TATA box (similar to mTARC).
Constructs containing sites in forward and reverse orien-
tations were identified. When co-transfected with STAT6
into RAW 264.7 cells (Figure 6), trimers of T1 or T6 in
either the forward (3XT1 F and 3XT6 F) or reverse orienta-
tions (data not shown) were not induced by IL-4 at all. In
contrast, trimers of T2, T4 and T11 were induced by IL-4
regardless of insert orientation (data shown for forwards
orientation only, 3XT2 F, 3XT4 F and 3XT11 F). The T4
trimer was only minimally induced by IL-4 (~3.5-fold),
whereas T2 and T11 trimers were more highly induced
than the mTARC -1173 full-length promoter construct.
Thus, sites equally capable of binding STAT6 in vitro can
have quite disparate capacity for activation by IL-4 in Mθ
when assayed by transfection.
To resolve the contribution of individual putative STAT6
sites to overall mTARC promoter IL-4 inducibility, we per-
formed site-directed mutagenesis of key sites within the
context of the full-length -1173 promoter. The T1, T2, T4,
T5, T6 and T11 sites were mutated, as these sites were
implicated as strong candidate functional STAT6 by previ-
ous experiments (see above). As the 5' TTC nucleotide tri-
plet is highly conserved amongst both published STAT6
sites [40,59,60] and all mTARC putative sites capable of
Constructs containing trimers of mTARC STAT6-binding sites are induced to varying degrees by IL-4 Figure 6
Constructs containing trimers of mTARC STAT6-binding sites are induced to varying degrees by IL-4. RAW 
267.4 cells were transfected as described in Figure 4A with 5 μg luciferase-conjugated mTARC STAT6 site trimers and 3 μg 
STAT6 expression vector. E denotes the Emr1 minimal promoter and T1-11 denote mTARC putative STAT6 sites within the 
constructs. F refers to the forward orientation of the promoter. Data are representative of at least 2 transfections and results 
are displayed as fold induction of sample relative luciferase activity (luciferase/β-galactosidase) with cytokine treatment +/- SD.
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binding STAT6 in EMSA experiments, this sequence was
mutated to 5' AAC in order to abrogate STAT6 binding
[61]. Mutant and wild-type sequence information was
compared using the Genomatix MatInspector [62] to con-
firm that mutagenesis did not create new transcription
factor binding sites that could alter the IL-4 responsive-
ness of the constructs (data not shown). Each mutant con-
struct was co-transfected with STAT6 into RAW 264.7 cells
and stimulated with IL-4 for 18 hours (Figure 7).
This assay confirmed that T1 and T2 are of critical impor-
tance to the IL-4 induction of mTARC -1173. Mutation of
T2 resulted in complete abrogation of promoter activation
by IL-4, whereas T1 mutation reduced promoter fold
induction by IL-4 from 12-fold (mTARC -1173 wild-type)
to 2-fold. This is consistent with results shown in Figures
4 and 5, but in contrast with the functional activity of the
isolated T1 trimer in Figure 6. Mutation of T4 reduced pro-
moter IL-4 induction by 40%, indicating, as suggested by
Figures 4 and 6, that T4 contributes less significantly than
T1 and T2 to the overall IL-4 induction. Similarly,
although T11 bound STAT6 in EMSA and was potently
activated by IL-4 as an isolated trimer, it does not appear
to have significant activity within the context of mTARC -
1173 (Figures 4 and 6). Interestingly, mutation of either
T5 or T6 significantly reduced mTARC -1173 promoter IL-
4 induction from 12-fold to 4-fold, demonstrating that
these sites do contribute to overall IL-4 induction (con-
sistent with Figure 4), even though they cannot bind or be
activated by STAT6 when isolated from the promoter.
Thus, the functional activity of STAT6 sites in isolation
may be distinct from their functional activity within the
context of their endogenous promoter. A summary of this
data is compiled in Table 1.
Site-directed mutagenesis reveals a critical role for T1 and T2 and significant contributions from T4, T5 and T6 sites in the IL-4  induction of mTARC -1173 Figure 7
Site-directed mutagenesis reveals a critical role for T1 and T2 and significant contributions from T4, T5 and 
T6 sites in the IL-4 induction of mTARC -1173. RAW 264.7 cells were transfected as described in Figure 4A with 5 μg 
luciferase-conjugated mutant constructs (T1-11 mutant) and 3 μg STAT6 expression vector. Data are representative of at 
least 2 transfections and results are displayed as fold induction of sample relative luciferase activity (luciferase/β-galactosidase) 
with cytokine treatment +/- SD.
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mTARC STAT6 sites on heterologous minimal promoters are potent IL-4 responders Figure 8
mTARC STAT6 sites on heterologous minimal promoters are potent IL-4 responders. RAW 264.7 cells were 
transfected as described in Figure 4A with 5 μg promoter-luciferase constructs indicated and 3 μg STAT6 expression vector. E 
denotes the Emr1 minimal promoter and A denotes the EIF-4A1 minimal promoter. The 5XST6 constructs consist of 394 bp 
murine TARC sequence from position -132 (refer to Figure 3) to -526 and contain 5 of the putative STAT6 sites. The 9XST6 
constructs consist of 736 bp murine TARC sequence from position -132 (refer to Figure 3) to -868 and contain 9 of the puta-
tive STAT6 sites. F refers to the forward orientation of the promoter. Cells were treated +/- 20 ng/ml recombinant murine IL-
4 (A) or IL-4 doses stated (B) for 18 hours before being harvested and assayed for luciferase and β-galactosidase activity. Data 
are representative of at least 2 transfections (A) or standardised results from multiple transfections (B) and results are dis-
played as fold induction of sample relative luciferase activity (luciferase/β-galactosidase) with cytokine treatment +/- SD.
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Murine TARC STAT6 sites in their natural configuration 
constitute potent IL-4 response elements
We next tested whether the natural configuration of sites
within the mTARC promoter could confer IL-4 inducibil-
ity on heterologous promoters and hence act as a transfer-
able IL-4 response element. The Emr1 -40 (non TATA box)
and the EIF4A1 -40 (TATA box) [63] minimal promoters
were selected as neither was induced by IL-4 nor had
strong basal activity when transfected into RAW 264.7
cells (Figure 8A). To assess the significance of the distal
(non-binding) putative STAT6 sites and potential cooper-
ation between the T5 and T6 sites in enhancing mTARC
induction by IL-4, promoter constructs covering two dif-
ferent regions of the mTARC proximal promoter were
designed. One region from position -132 (refer to Figure
3) to -526 contained the five most proximal putative
STAT6 sites and bisected the sequence containing T5 and
T6. A second region from position -132 to -868 contained
nine putative STAT6 sites and intact T5-T6 sequence. The
T11 site was not included in these constructs because it
had not appeared significant in the experiments shown in
Figure 7. Constructs were synthesised containing either
the five (5XST6) or the nine (9XST6) putative STAT6 sites
on each heterologous minimal promoter in both forward
and reverse orientations.
When co-transfected with STAT6 into RAW 264.7 and
stimulated with IL-4 (Figure 8A), these mTARC promoter
elements were able to confer potent IL-4 inducibility on
both the Emr1 and the EIF-4A promoters. Interestingly,
only sites inserted in the forward orientation were
induced by IL-4 (reverse constructs not shown). The
9XST6 constructs gave 95-135-fold induction with IL-4,
whereas the 5XST6 constructs gave only 8-25-fold induc-
tion with IL-4. This suggests that distal mTARC promoter
sites do contribute to the overall IL-4 response, possibly
via cooperative interactions [41,64-67].
To examine the potency of the most IL-4 inducible con-
struct, Emr1 9XST6 F, we performed dose-response exper-
iments. The full-length mTARC -1173 and the Emr1
9XST6 F construct were transfected into RAW 264.7 cells
and treated with IL-4 concentrations ranging from 0.01–
20 ng/ml. Both constructs gave characteristic sigmoidal
response curves that began to plateau above 5 ng/ml IL-4
(Figure 8B). The Emr1 9XST6 F construct showed greater
induction by IL-4 than mTARC -1173 at all concentrations
used above 0.25 ng/ml, which appeared to be the lower
limit of the response. Importantly, the Emr1 9XST6 F con-
struct still demonstrated a 40-fold induction with concen-
trations of IL-4 as low as 1 ng/ml, demonstrating that
mTARC promoter sequences constitute a very sensitive IL-
4 response element.
Discussion
In this paper, we have shown for the first time that expres-
sion of the CC chemokine mTARC/CCL17 is potently and
rapidly induced by IL-4 in primary murine macrophages
and that this induction does not require de novo protein
synthesis. TARC expression by alternatively-activated Mθ
therefore represents an early component of Th2 inflam-
matory responses, which is exaggerated by further TARC
expression by DC [30,31] and Th2 T-cells [43]. As TARC
may represent an important therapeutic target in chronic
allergic pathologies [22-24], we have analysed the mecha-
nisms underlying its IL-4 induction in Mθ in some detail.
Our experiments have revealed that synergistic interac-
tions between at least five STAT6 sites within 1 kb of the
mTARC transcriptional start site contribute to IL-4 regula-
tion.
Table 1: Summary of results for mTARC putative STAT6 sites
Putative site Position within 
mTARC promoter
Sequence Significance inferred 
from 5 'deletion series
Binds STAT6 in 
EMSA
Trimer construct 
induced by IL-4 in 
transfections
Reduction in IL-4 induction of 
mTARC -1173 when site 
mutated (approx.)
T1 -140 to -148 TTCTTTGAA* + +- 8 5 %
T2 -194 to -203 TTCTCTGGAA + ++ + 1 0 0 %
T3 -473 to -482 ATCCCTGTAA - -N D N D
T4 -484 to -493 TTCTACTGAA - ++ 4 0 %
T5 -513 to -522 TTCCCCAAAA + -N D 6 0 %
T6 -531 to-540 TTCAGCTGAA + -- 6 0 %
T7 -657 to -666 TTTCTGGGAG - -N D N D
T8 -763 to -111 TTCTAGGGCA - -N D N D
T9 -854 to -863 TTCTGGGCAC - -N D N D
T10 -870 to -879 TTGTCCTGAA - -N D N D
T11 -904 to -913 TTCTCAGTAA - ++ + 1 5 %
*residues in bold conform to the core consensus STAT6 binding site.
+ indicates positive result.
- indicates negative result.
++ indicates highly activated by IL-4.
ND indicates experiment not done.BMC Molecular Biology 2006, 7:45 http://www.biomedcentral.com/1471-2199/7/45
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By real-time PCR, we measured significant up-regulation
of mTARC mRNA within 4 hours of IL-4 stimulation, sug-
gesting that Mθ expression of TARC is likely to be of con-
siderable importance in the swift establishment of Th2
responses in vivo. This IL-4 induction was found to be
dependent on expression of STAT6, a transcription factor
strongly implicated in chronic Th2 pathologies including
asthma [32,68-70]. TARC expression correlates with dis-
ease severity in many asthma patients [17-19,71]; and is
one of the few chemokines found to be truly STAT6-
dependent [70], hence the data presented here substanti-
ate the link between TARC and STAT6 in disease and may
suggest means by which TARC expression could be mod-
ulated for therapeutic benefit. STAT-mediated transcrip-
tion is tightly regulated by intracellular suppressors [72-
76]. The IFN-γ-mediated inhibition of mTARC expression
may result from up regulation of SOCS1 [77,78], which
we found inhibited the IL-4 induction of mTARC -1173 in
RAW 264.7 cells (data not shown). SOCS1 is also up reg-
ulated by IL-4 [79,80], and so our observations of mTARC
superinduction by IL-4 in the presence of cycloheximide
could be related to reduced expression of this factor.
Induction of mTARC by IL-4 is mediated by multiple STAT6 
sites within the proximal promoter
No de novo protein synthesis was required for the IL-4
induction of mTARC, indicating direct interaction of
STAT6 with the mTARC promoter. This was confirmed by
ChIP experiments revealing STAT6 bound to the endog-
enous mTARC promoter in IL-4-treated Mθ. Fulkerson et
al. [70] identified mTARC (CCL17) as a CC chemokine
induced early in the lung in an allergen challenge model
of asthma and using STAT6 deficient mice showed that
mTARC expression in this disease model was STAT6
dependent. During the preparation of this manuscript,
Wirnsberger et al. [43] reported the involvement of two
STAT6 sites (one corresponding to the T2 site in our
study) in the IL-4-mediated regulation of TARC in human
T lymphocytes, but did not investigate the additional
highly conserved proximal T1 site that we identified. The
authors identified these STAT6 sites by 'visual inspection'
rather than systematic analysis using transcription factor
search engines and so the data do not exclude the possi-
bility of more distal functional STAT6 sites that may
diverge from strict consensus sequence [81]. We identified
eleven putative STAT6 sites within the mTARC proximal
promoter and determined that five of these had func-
tional activity within the context of the mTARC -1173
construct. Hence the regulation of mTARC by IL-4 is more
complex than previous work suggests, involving multiple
STAT6 sites. To our knowledge, such interaction between
STAT6 sites has only previously been reported for the pro-
moter of the SOCS1 gene [80].
Of the five functional STAT6 sites identified, the two sites
conserved between human and mouse, T1 and T2, were
found to be important mediators of the mTARC induction
by IL-4, even though T1 is not considered a classical
STAT6 binding site [43]. By site-directed mutagenesis, T2
was shown to be absolutely essential for IL-4 induction of
the mTARC promoter and mutation of T1 in the context
of the -1173 promoter resulted in an 85% reduction in
promoter induction by IL-4. The significance of the T2 site
was predicted from its perfect TTC(N)4GAA consensus
STAT6-binding sequence and ability to bind and be acti-
vated by STAT6 as an isolated site. In contrast, the T1 site
has TTC(N)3GAA spacing, previously associated with
weak or inhibitory activity when occupied by STAT6
[33,82], and also could not be activated by IL-4 as an iso-
lated site, even though it bound STAT6.
Three additional sites (T4, T5 and T6) were found to sup-
port the IL-4 induction of mTARC to a lesser extent than
T1 and T2, even though both T4 and T6 are perfect con-
sensus STAT6-binding sites. Interestingly, the T5 imperfect
STAT6 site was found to have equivalent function to T6
within the context of the mTARC -1173 promoter and the
significance of both sites did not correlate with their
capacities for STAT6 binding in EMSA. Thus, the findings
of this paper sound a cautionary note for prediction of
STAT6 site function from sequence data alone and
emphasise the importance of adopting multiple
approaches for the analysis of STAT6-mediated gene tran-
scription. Notably, STAT6 has also been shown to bind to
an imperfect palindrome site in the delta-opioid receptor
[81], suggesting that functional STAT6 sites in other genes
are also not restricted to a simple TTC(N)4GAA consensus
sequence and cannot be identified as such.
The involvement of five closely-apposed STAT6 sites in
the IL-4 induction of mTARC suggests that overall pro-
moter induction may result from interactions between
sites. Cooperation between proximal STAT6 sites in the
SOCS1 promoter has been described [80] and other STAT
proteins have similarly been shown to interact to activate
gene transcription [41,64-67]. This arrangement of func-
tional sites may stabilise STAT6 binding to low-affinity or
non-canonical sites, such as T5, enhancing the overall
transcriptional response to IL-4. Obligate stabilising inter-
actions between STAT6 dimers bound at the juxtaposed
T5 and T6 sites may explain the lack of STAT6 binding to
these sites in isolation, as well as the comparable reduc-
tion in promoter induction by IL-4 when either site was
mutated.
From our analyses of the functional activity of mTARC
STAT6 sites, we were able to generate transferable pro-
moter elements that conferred potent IL-4 responsiveness
on two heterologous promoters. Constructs containingBMC Molecular Biology 2006, 7:45 http://www.biomedcentral.com/1471-2199/7/45
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five mTARC putative STAT6 sites and intervening pro-
moter sequences in their endogenous arrangement
(5XST6) were induced up to 95-fold by IL-4, whereas con-
structs containing nine sites (9XST6) were induced up to
135-fold. The significantly greater activation of the 9XST6
constructs containing both T5 and T6 sites than the 5XST6
constructs lacking T6 may have resulted from interactions
between the T5 and T6 sites. Although the 5XST6 con-
structs contained the T1, T2, T4 and T5 functionally signif-
icant STAT6 sites, stimulation with IL-4 resulted in
promoter activity that was only 10–20% that of the 9XST6
constructs. Thus, distal promoter regions play an impor-
tant role in mTARC induction by IL-4. Importantly, the
potent IL-4 inducibility of these heterologous promoter
constructs suggests that mTARC-derived IL-4 responsive
elements could be used to direct IL-4-inducible gene
expression in vivo with potential scientific and therapeutic
benefit.
Conclusion
In summary, we have demonstrated that Th2 cytokines
regulate murine TARC by a direct-acting STAT6 pathway.
We have shown that the mTARC promoter contains mul-
tiple functional STAT6 sites with heterogeneous capacity
for binding of STAT6 and transcriptional activation. The
sites conserved between human and mouse TARC pro-
moters are the most crucial for the IL-4 induction of
mTARC, but distal sites also play a significant role. Impor-
tantly, sites with imperfect consensus sequence have been
shown to be functional, suggesting that the analysis of
other STAT6-regulated genes may be warranted. These
findings have also allowed us to develop highly respon-
sive IL-4-inducible elements, significantly more active
than those generated from multimerised individual
STAT6 sites [33,83], which could be exploited direct trans-
gene expression in alternatively activated macrophages in
vivo.
Methods
Cells
All experiments were carried out according to Home
Office guidelines and with appropriate local ethical
approval. Male C57BL/6, BALB/c or STAT6-/- [51] mice (8–
12 weeks) were injected i.p. with 1 ml BIOgel beads (Bio-
Rad) in PBS 2% w/v or thioglycollate broth (Difco) and
elicited peritoneal macrophages (Mθ) were harvested by
lavage with PBS/5 mM EDTA on day 4. Cells were usually
plated at 2 × 106 Mθ per 35 mm dish in OptiMEM (Invit-
rogen) (determined by MTT1 assay [84,85] to promote
optimal cell viability over 72 hours) supplemented with
L-glutamine and penicillin/streptomycin. Cells were
washed 2 hours after plating and used in assays after 24
hours at 37°C. Cells were treated with recombinant
cytokines (R&D Systems) or LPS (S. typhimurium, Sig-
maAldrich) at the concentrations and time periods stated.
RAW 264.7 cells were cultured in RPMI (Invitrogen) sup-
plemented with L-glutamine, penicillin/streptomycin,
and 10% foetal calf serum. Cells were plated at 2 × 106
cells per 35 mm dish and left at 37°C for 30 minutes to
adhere before cytokine treatment.
RT-PCR and real-time PCR
Total RNA was prepared by scraping cells into RNAzol
(Biogenesis) according to manufacturer's instructions.
RNA was DNAse-treated (Promega) and 1 μg was reverse
transcribed using primer (dT)15  for cDNA synthesis
(Roche) and M-MLV-RT enzyme (Promega). Resultant
cDNA was used in 20 μl final volume semi-quantitative
PCR reactions using Red Hot DNA Polymerase enzyme
and reaction mix (ABGene), supplemented with 1.5 mM
MgC12, 0.2 mM each dNTP and 0.3 μM forward and
reverse primers. Primers for semi-quantitative PCR were as
follows:  β2M1(β2-microglobulin): 5' TGACCGGCTTG-
TATGCTATC and 5' CAGT GTGAGCCAGGATATAG (222
bp) and mTARC: 5' ATGAGGTCACTTCA GATGCT and 5'
AGGTCACGGCCTTGGGTT TT (284 bp) mTARC: 5' GCT-
GCCGTCATTTTCTGCCT and 5' GCTAAACGCTTTCAT-
TAAAT.  IP-10: 5' GCTGCCGTCATTTTCTGCCT and 5'
GCTAAACGCTTTCATTAAAT. β2M was amplified from 1
μl (~20 ng) cDNA in a 24 cycle PCR program with cycling
conditions as follows: 95°C for 30 seconds, 54°C for 30
seconds, 72°C for 30 seconds. Normalised template vol-
umes were subjected to 31–35 PCR cycles using mTARC
and IP-10 primers.
Real-time PCR was carried out with 2.5 μl (~50 ng) cDNA
in multiplex reactions containing both mTARC and
HPRT1  (hypoxanthine guanine phosphoribosyl trans-
ferase) primers (at 0.3 μM each) and fluorogenic probes
(at 0.2 μM each) in 25 μl final volumes of Universal Mas-
terMix kit (PE Applied Biosystems). Primer and probe
sequences were as follows: HPRT: 5' GACCGG TCCCGT-
CATG, probe ACCCGCAGTCCCAGCGTCGTG and 5'
TCATAACCTGGTTCATC ATCGC and mTARC: 5' GGGAT-
GCCATCGTGTTTCTG, probe CTGTCCAGGGCAAGCT
CATCTGTGC and 5' GCCTTCTTCACATGTTTGTCTTTG.
PCR and TaqMan analyses were performed using the ABI/
PRISM 7700 sequence detector system (PE Applied Bio-
systems). Reactions were carried out in triplicate on 96-
well plates with PCR cycling conditions: 50°C for 2 min-
utes, 95°C for 10 minutes, then 95°C for 15 seconds,
62°C for 1 minute for 50 cycles. Relative mTARC cDNA
copy number was interpolated from a standard curve gen-
erated from cycle threshold values of serial dilutions of a
known mTARC-containing cDNA sample and normalised
to relative HPRT copy number.
Enzyme-Linked Immunosorbent Assay (ELISA)
C57BL/6 BIOgel-elicited Mθ were cultured in 1 ml supple-
mented OptiMEM, which was removed at specified timeBMC Molecular Biology 2006, 7:45 http://www.biomedcentral.com/1471-2199/7/45
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points, centrifuged at 16000 g at 4°C for 1 minute to
remove cell debris and then frozen in aliquots at -70°C.
ELISA was carried out with 50 μl each supernatant sample
using the mouse TARC/CCL17 Quantikine kit (R&D Sys-
tems). Samples were analysed in duplicate at 450 nm. Lev-
els of mTARC protein in unknown samples were
quantified by interpolation from a standard curve gener-
ated in the same experiment.
Chromatin immunoprecipitation (ChIP)
Balb/c bone marrow Mθ were cultured for 7 days in L cell-
conditioned medium. Cells were treated with 10 ng/ml
recombinant murine IL-4 for the times indicated prior to
formaldehyde fixation and sonication as described previ-
ously [86]. Immunoprecipitation was performed using
the M20 anti-STAT6 antibody (Santa Cruz) followed by
reversal of cross-linking and PCR amplification of the
proximal TARC promoter using the mTARC primers 5'
GAGGTGACCTATTTAACCTCTC and 5' GAAGTAAGT-
CATTGCCCTTACC An M20 STAT6 blocking peptide
(Santa Cruz) was used to confirm the specificity of the
immunoprecipitation.
Translation inhibition experiments
C57BL/6 thioglycollate-elicited Mθ were treated with 0,
0.5, or 1 μg/ml cycloheximide (BDH) for 2 hours prior to
addition or not of 20 ng/ml recombinant murine IL-4.
Cells were incubated at 37°C for 4 or 24 hours before
RNA was harvested and processed for real-time PCR.
Identifying putative STAT6 binding sites in the murine 
TARC promoter
Mouse chromosome 8 sequence information was
obtained from the Celera database and verified using the
Sanger Centre database [52]. Murine sequence was
aligned with the homologous human chemokine cluster
on chromosome 16q13 to search for conserved sequence
amongst the human and murine TARC promoters.
Sequences were analysed for potential transcription factor
binding sites using Genomatix MatInspector [62].
Luciferase constructs and transient transfections
Murine TARC promoter fragments were PCR amplified
from 200 ng C57BL/6 genomic DNA sample using a 1:1
ratio of Herculase Enhanced DNA Polymerase (Strata-
gene) and Taq Polymerase (Gibco BRL) in 25 μl reactions
containing 1% DMSO, 0.2 μM each dNTP and 100 ng/ml
each primer. The reverse primer for full-length (-24 to -
1173) and 5' deletion series mTARC promoter constructs
was: 5' AACTAAGCTTTCTTCATGGGTCCTTCTGCCT. For-
ward primer sequences were as follows: -1173: 5' AAC-
TACGCGTTCTGCTAGCACATG AGTGCAA, -839: 5'
AACTACGCGTTGGGTATGCTGAAAATTCACA,  -649: 5'
AACTAC GCGTTTCCAACCCACTAAAGCACA, -498: 5'
AACTACGCGTGCCT CTTCTACTGAAC A, -467: 5' AAC-
TACGCGTTCACCCTCCTGTGGACCTTCT and -128: 5'
AACTACGCGTT GGAAGGATTATAGGAGGGGA. Purified
PCR products were digested with Mlu I and Hind III and
cloned into pGL3 Basic (Promega), which contains the
firefly luciferase gene.
Site-directed mutagenesis was carried out by 2-stage PCR
using mTARC -1173 forward and reverse cloning primers
noted above and forward and reverse primers designed to
introduce 2-base pair mutations within selected mTARC
STAT6 sites. The mutant primers were as follows (base
changes underlined): T1: 5' AGTTATCTCAAAAACTT
TGAATTTCT and 5' AGAAATTCAAAGTTTTTGAGATAACT,
T2: 5' GTCGAGTG ACCAAACTCTGGAAAGCC and 5'
GGCTTTCCAGAGTTTGGTCACTCGAC,  T4: 5'
GGACTAGGCCTCAACTACTGAACA TC and 5' GATGT-
TCAGTAGTTGAG GCCTAGTCC, T5: 5' TGAACCTCT-
GGGAACCCCAAAATAGG and 5' CCTATTTT
GGGGTTCCCAGAGGTTCA,  T6: 5' GACAGGCTCAG-
CAACAGCTGAACCTC and 5' GAGGTTCAGCTGTTGCT-
GAGCCTGTC,  T11: 5' GCCGGTTCTTTAACTCAGTA
AACCC and 5' GGGTTTACTGAGTTAAAGAACCGGC. In
the first stage, two PCR reactions were carried out to gen-
erate mutants of each site: mTARC -1173 forward with
mutant reverse and mutant forward with mTARC -1173
reverse. The products of these reactions were used in a 1:1
ratio as template for the second-stage PCR reaction using
only mTARC -1173 forward and reverse cloning primers.
The final PCR products were purified and digested with
Hind III and Mlu I and cloned into pGL3 Basic.
Primers and oligonucleotides for 9XST6 and 5XST6 deriv-
ative constructs were designed to create 5' and 3' Mlu I
sites for bi-directional cloning onto Emr1 -40 [58] and
EIF4A1 -40 [63] minimal promoters in the pGL3 Basic
vector (Promega). The minimal promoters were modified
by addition of an Mlu I linker sequence (5' CACGCGT-
GGT AC) for ease of cloning. The reverse primer sequence
for the 9XST6 and 5XST6 PCR reactions was: 5' AAC-
TACGCGTAGAGAAATTCAAAGAATTTGAGA and the for-
ward primers were: 9XST6: 5'
AACTACGCGTCTCTTTTCTGGGCACTGTTGT and
5XST6: 5' AACTACGCG TTGGGTTCCCCAAAATAGGGT.
Trimerised mTARC STAT6 site constructs were generated
by random self-ligation of 5'-phosphorylated, PAGE-puri-
fied trimers of the T1, T2, T4, T6 and T11 site oligonucle-
otides used as probes in the EMSA experiments (see below
for sequences). These trimers were designed to create 5'
and 3' Mlu I sites when annealed to form double-stranded
DNA for cloning onto the Emr1 -40 minimal promoter
(as described above).
All plasmids were sequenced and prepared using Qiagen
or QBIOgene endotoxin-free kits to ensure levels of endo-BMC Molecular Biology 2006, 7:45 http://www.biomedcentral.com/1471-2199/7/45
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toxin contamination were ≤ 0.1 EU/μg. Transient transfec-
tions were carried out by electroporation of RAW 264.7 as
described previously [33]. Ten million RAW 264.7 cells
were routinely co-transfected with 5 μg specific mTARC
luciferase promoter construct DNA and 3 μg of a murine
STAT6 expression vector (gift of Yoshihiro Ohmori [87]).
In all experiments, 1 μg β-galactosidase expression vector
was co-transfected as a control for transfection efficiency.
Cells were incubated for 16–18 hours post-transfection +/
- 20 ng/ml recombinant murine IL-4 before whole cell
extracts were harvested in 250 μl reporter lysis buffer
(Promega). Transfection results are shown as Relative
Luciferase Activity (luciferase/β-galactosidase) or fold
induction of this value with IL-4 treatment, as appropri-
ate.
Electrophoretic Mobility Shift Assays (EMSA)
C57BL/6 BIOgel-elicited Mθ were plated at l.5 × 107 cells
per 90 mm dish and treated +/-20 ng/ml either recom-
binant murine IL-4 or recombinant murine IFN-γ for 1
hour. Cells were washed and incubated at 4°C in PBS sup-
plemented with 5 mM EDTA and 0.2 mM PMSF for 15
minutes. Nuclear extracts were prepared by addition to
each dish of 1 ml nuclear extract buffer I containing 10
mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KC1, 0.5 mM
DTT, 0.2 mM PMSF and additional protease inhibitors.
Cells were incubated at 4°C for 15 minutes, then scraped
into this buffer and vortexed gently. Cells were centrifuged
at 2000 g for 30 seconds to recover the nuclei and the
supernatant was discarded. Pellets were resuspended in 25
μl nuclear extract buffer II containing 20 mM HEPES pH
7.9, 25% glycerol, 420 nM NaCl, 0.5 mM DTT, 0.2 mM
PMSF and protease inhibitors and left on ice for 20 min-
utes before being centrifuged at 16000 g for 15 minutes at
4°C. Supernatants from identical cytokine treatments
were pooled and frozen at -70°C until used. Protein con-
centration of extracts was quantified using a BCA kit
(Pierce) and 3 μg extract were used per EMSA assay.
Complementary forward and reverse oligonucleotides
were designed for each mTARC putative STAT6 site. The
forward sequences were as follows: T1 probe: 5' ATCT-
CAAATTCTTTGAATTTCTCTAG,  T2 probe: 5' AGTGAC-
CATTCTCTGGAAAGCCACAA,  T3 probe: 5'
TACTGAACATCCCTGTAACCTGCTCA, T4 probe: 5' TAG-
GCCTCTTCTACTGAACATCCCT G, T5 probe: 5' CCTCT-
GGGTTCCCCAAAATAGGGTGG,  T6 probe: 5'
GGCTCAGCTTCAGCTGAACCTCTGGG,  T7 probe: 5'
GTGCTCTATTTCTGGGAGCTGAGCTT,  T8 probe: 5'
CTATGGGCTTCTAGGGCAGCCTCTGG,  T9 probe: 5'
AAACTCTTTTCTGGGCACTGTTGTTA,  T10 probe: 5'
ATAGTGACTTGTCCTGAAACTCTTTT and T11 probe: 5'
GGTTCTTTTTCTCAGTAAACCCTGGC. Forward and
reverse oligonucleotides were annealed and end-labelled
with 32P (Amersham Pharmacia Biotech). Nuclear extracts
were incubated with labelled oligonucleotides in sample
buffer with final concentrations of 20 mM HEPES pH 7.9,
6.25% glycerol, 0.5 mM EDTA, 50 μg/ml poly dIdC, 50
μg/ml BSA and 12.5 μg/ml salmon sperm DNA for 15
minutes at room temperature. For supershift assays, 400
ng specific or control antibodies (Santa Cruz) were also
added to the EMSA reactions. For cold competition assays,
100-fold molar excess amounts of unlabelled oligonucle-
otides were added to appropriate reactions. Samples were
separated on a 7% polyacrylamide gel run at 250 V (20
mA) for 3 hours at 4°C and visualised after exposure to X-
ray film.
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